TwitterLinkedInYoutubeSlideshareflickrIFPMA - Global Health Matters - BlogRSS
IFPMA Home

International Federation of Pharmaceutical Manufacturers & Associations



Filters
<< FirstLast >>

Statement on Release on The Lancet Commission on Health and Climate Change Report

23 June 2015

IFPMA Statement, WHA 68, Item 11.2 Framework of engagement with non-State actors

26 May 2015

IFPMA Statement, WHA 68, Item 15.1 Antimicrobial resistance

22 May 2015

IFPMA Statement, WHA 68, Item 17.3, Substandard/spurious/falsely-labelled/falsified/counterfeit medical products

22 May 2015

LDCs request for extension of TRIPS implementation

29 April 2015

IFPMA Statement, WHO Executive Board 136 - Item 9.4, 2014 Ebola virus disease outbreak

04 February 2015

IFPMA Statement, WHO EB 136, Item 8.1, Antimicrobial Resistance

28 January 2015

IFPMA Statement, WHO EB 136, Item 5.1, Framework of engagement with non-State actors

27 January 2015

IFPMA Statement, WHO EB 136, Item 9.3, Global Vaccine Action Plan

27 January 2015

IFPMA Statement in support of 2015 Gavi Replenishment

20 January 2015

Mr Masafumi Nogimori, Speach at the Closing Session: Representative Director, Chairman of the Board, Astellas Pharma Inc., and Vice President of the IFPMA

04 November 2014

Dr Stefan Oschmann, Inaugural speech – transcript: Member of the Executive Board and Chief Executive Officer Pharma, Merck KGaA, Darmstadt, Germany, and President of IFPMA

04 November 2014

Filters
<< FirstLast >>
Filters
<< FirstLast >>

23 June 2015,

Statement on Release on The Lancet Commission on Health and Climate Change Report

Details

26 May 2015,

IFPMA Statement, WHA 68, Item 11.2 Framework of engagement with non-State actors

Details

22 May 2015,

IFPMA Statement, WHA 68, Item 15.1 Antimicrobial resistance

Details

22 May 2015,

IFPMA Statement, WHA 68, Item 17.3, Substandard/spurious/falsely-labelled/falsified/counterfeit medical products

Details

29 April 2015,

LDCs request for extension of TRIPS implementation

Details

04 February 2015,

IFPMA Statement, WHO Executive Board 136 - Item 9.4, 2014 Ebola virus disease outbreak

Details

28 January 2015,

IFPMA Statement, WHO EB 136, Item 8.1, Antimicrobial Resistance

Details

27 January 2015,

IFPMA Statement, WHO EB 136, Item 5.1, Framework of engagement with non-State actors

Details

27 January 2015,

IFPMA Statement, WHO EB 136, Item 9.3, Global Vaccine Action Plan

Details

20 January 2015,

IFPMA Statement in support of 2015 Gavi Replenishment

Details

04 November 2014,

Mr Masafumi Nogimori, Speach at the Closing Session: Representative Director, Chairman of the Board, Astellas Pharma Inc., and Vice President of the IFPMA

Details

04 November 2014,

Dr Stefan Oschmann, Inaugural speech – transcript: Member of the Executive Board and Chief Executive Officer Pharma, Merck KGaA, Darmstadt, Germany, and President of IFPMA

Category: Presidency, News

Details
Filters
<< FirstLast >>